Evidence map›Paper›PMID 42688829›Full record

ArticleFrontiers in immunology2026

Development of humanized mouse models for the preclinical evaluation of NK cell-based therapies.

Pauline Rettman, Samira Benhamouche-Trouillet, Georges A Azar, Dorothée Bourges, Valeria Fantin, Sukhvinder S Sidhu, Céline Nicolazzi

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pauline RettmanSanofi Immuno-Oncology Research, Vitry-sur-Seine, France.
Samira Benhamouche-TrouilletSanofi Immuno-Oncology Research, Vitry-sur-Seine, France.
Georges A AzarSanofi Immuno-Oncology Research, Vitry-sur-Seine, France.
Dorothée BourgesSanofi Immuno-Oncology Research, Vitry-sur-Seine, France.
Valeria FantinSanofi Immuno-Oncology Research, Cambridge, MA, United States.
Sukhvinder S SidhuSanofi Immuno-Oncology Research, Vitry-sur-Seine, France.
Céline NicolazziSanofi Immuno-Oncology Research, Vitry-sur-Seine, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Novel immunotherapeutic strategies engaging human Natural Killer (huNK) cells have emerged as a promising treatment paradigm; however, their accurate preclinical evaluation requires reliable mouse models capable of supporting functional huNK cell engraftment. Methods: We developed and characterized robust Results: Our NK-humanized mouse models were developed using in vitro amplified huNK cells, which facilitated the production of large number of viable and functional huNK cells and allowed the engraftment of greater cohort of mice. We identified several key parameters improving the long-term persistence and proliferation of functional huNK cells that maintain important functional cell surface markers. FcγR-KO mice exclusively modeled the ADCC potential of huNK cells without the confounding contribution of mouse immune cells. The introduction of a pre-transfer resting period improved tolerability and circumvented potential donor-dependent toxicity issues. Engrafted huNK cells were successfully mobilized in vivo by different NK-based therapeutics, including an engineered IL-2 and an ADCC-enhanced monoclonal antibody. Discussion: The NK-humanized huIL-15 Tg mouse models developed here provide a versatile and translationally relevant platform for the evaluation and selection of NK cell-based drug candidates, improving clinical translatability and offering a robust framework for preclinical assessment of novel NK cell immunotherapies.

Indexed as

Immunotherapy, AdoptiveKiller Cells, NaturalAnimalsAntibody-Dependent Cell CytotoxicityDisease Models, AnimalHumansInterleukin-15MiceMice, KnockoutMice, TransgenicReceptors, IgGIL15 protein, humanInterleukin-15Receptors, IgGhuIL-15 transgenic micein vivo modelsmonoclonal antibodiesNatural Killer cellsNK cell-based therapiesNK-humanized mouse model

Identifiers

PMID42688829
PMCPMC13535524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.